Industry

Nanoscope Therapeutics Secures Orphan Drug Designation in Saudi Arabia for MCO-010

Eyewire+3d ago1 min read

Nanoscope Therapeutics announced it has received Orphan Drug Designation in the Kingdom of Saudi Arabia for its lead candidate, MCO-010, for the treatment of inherited retinal dystrophies (IRDs) associated with severe vision loss. The company is advancing MCO-010 as a potential first-in-class optogenetic therapy designed to restore vision regardless of the underlying genetic cause of disease. “MCO-010 development as a disease-agnostic optogenetic therapy continues to progress with regulatory authorities worldwide,” said Samarendra Mohanty, PhD, President and Chief Scientific Officer of Nanoscope Therapeutics. “With this designation in Saudi Arabia, we are further accelerating our efforts to bring this therapy to patients globally, including in regions where access to advanced retinal treatments has historically been limited.” The Saudi designation builds on a series of regulatory milestones across major international markets. In the United States, MCO-010 has received Orphan Drug and Fast Track designations for retinitis pigmentosa, as well as Orphan Drug, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT) designations for Stargardt disease. The company has also initiated a rolling Biologics License Application (BLA) for retinitis pigmentosa. Across Europe, the European Medicines Agency has granted five Orphan Drug designations covering multiple inherited retinal dystrophies, supporting Nanoscope’s disease-agnostic development strategy.

Read full article on Eyewire+

AI Summary

Quick Take

Nanoscope Therapeutics has secured Orphan Drug Designation in Saudi Arabia for MCO-010, a first-in-class optogenetic therapy for inherited retinal dystrophies (IRDs). This designation facilitates the expansion of a "disease-agnostic" treatment approach designed to restore vision in patients with severe loss regardless of their specific underlying genetic mutation.

Why It Matters

The current landscape for inherited retinal disease treatment is largely defined by mutation-specific gene therapies, which only address a small fraction of the patient population. MCO-010 represents a significant shift toward mutation-independent treatment, potentially offering a solution for the vast majority of IRD patients who currently have no therapeutic options. By securing regulatory milestones in Saudi Arabia alongside the US and Europe, Nanoscope is positioning this therapy for a global market, particularly in regions where genetic diversity and limited access to specialized ocular biologics have historically hindered care.

Key Details

MCO-010 is an optogenetic therapy designed to restore vision by making retinal cells light-sensitive, bypassing the need for specific gene correction.
The Saudi Arabian Orphan Drug Designation follows similar high-priority statuses in the U.S., including Fast Track and Regenerative Medicine Advanced Therapy (RMAT) for Stargardt disease.
Nanoscope has already initiated a rolling Biologics License Application (BLA) with the FDA for the treatment of retinitis pigmentosa.
The European Medicines Agency (EMA) has granted five Orphan Drug designations to the therapy, covering a broad range of inherited retinal dystrophies.
The therapy is specifically targeted at patients suffering from severe vision loss due to advanced retinal degeneration.

Practice Implications

Clinicians should note that MCO-010's disease-agnostic nature may eventually simplify the referral process for IRD patients who do not qualify for current mutation-specific treatments like voretigene neparvovec. While genetic testing remains the gold standard for diagnosis, this therapy could provide a viable pathway for patients with rare or unidentified mutations once regulatory approvals are finalized.

Who's Affected

Retina SpecialistsGenetic CounselorsLow Vision SpecialistsClinical ResearchersPractice Owners

What's Next

Nanoscope is continuing its rolling BLA submission for retinitis pigmentosa in the United States. Practitioners should watch for updates on the clinical data supporting these global regulatory filings and the potential for MCO-010 to become the first commercially available optogenetic therapy.

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.